Cantargia (CAN10 IL1RAP Immunology Program) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Cantargia (CAN10 IL1RAP Immunology Program) General Information

Description

Early-clinical stage immunology program based in Tokyo, Japan. The CAN10 antibody binds strongly to its target, IL1RAP, and has a unique capability to simultaneously inhibit the signaling of cytokines from the IL-1 superfamily, including IL-1, IL-33, and IL-36.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Lund
  • Sweden
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Corporate Office
  • Lund
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cantargia (CAN10 IL1RAP Immunology Program) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cantargia (CAN10 IL1RAP Immunology Program)‘s full profile, request access.

Request a free trial

Cantargia (CAN10 IL1RAP Immunology Program) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cantargia (CAN10 IL1RAP Immunology Program)‘s full profile, request access.

Request a free trial

Cantargia (CAN10 IL1RAP Immunology Program) FAQs

  • Where is Cantargia (CAN10 IL1RAP Immunology Program) headquartered?

    Cantargia (CAN10 IL1RAP Immunology Program) is headquartered in Lund, Sweden.

  • What industry is Cantargia (CAN10 IL1RAP Immunology Program) in?

    Cantargia (CAN10 IL1RAP Immunology Program)’s primary industry is Buildings and Property.

  • Is Cantargia (CAN10 IL1RAP Immunology Program) a private or public company?

    Cantargia (CAN10 IL1RAP Immunology Program) is a Private company.

  • What is the current valuation of Cantargia (CAN10 IL1RAP Immunology Program)?

    The current valuation of Cantargia (CAN10 IL1RAP Immunology Program) is .

  • What is Cantargia (CAN10 IL1RAP Immunology Program)’s current revenue?

    The current revenue for Cantargia (CAN10 IL1RAP Immunology Program) is .

  • Who are Cantargia (CAN10 IL1RAP Immunology Program)’s investors?

    Cantargia has invested in Cantargia (CAN10 IL1RAP Immunology Program).

  • When was Cantargia (CAN10 IL1RAP Immunology Program) acquired?

    Cantargia (CAN10 IL1RAP Immunology Program) was acquired on 11-Sep-2025.

  • Who acquired Cantargia (CAN10 IL1RAP Immunology Program)?

    Cantargia (CAN10 IL1RAP Immunology Program) was acquired by Otsuka Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process